RxDoctor Payments Data

Sandra Geubelle, PA

Physician Assistant · Rio Rancho, NMNPI 1154474401

Payments from drug & device makers

$1,294in general payments, 2019–2025

Across 63 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nxstage Medical, Inc.$264
  • AstraZeneca$246
  • Daiichi Sankyo Inc.$197
  • Bayer$126
  • Vifor Pharma, Inc.$105
  • Amgen$104
  • plus $254 from 6 others

What the payments were for

  • Food & beverage$1,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,294 in reported general payments places this provider in the 80th percentile of 635 physician assistant providers in New Mexico.

See all physician assistant providers in New Mexico

Medicare billing

Part B allowed, 2024
$29,754
Medicare patients
188
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban30$40,209
OzempicSemaglutide32$30,087
EliquisApixaban28$24,862
TrulicityDulaglutide17$23,956
FarxigaDapagliflozin Propanediol13$18,463
MyrbetriqMirabegron24$15,347
Fluticasone Propionate HfaFluticasone Propionate27$5,194
Atorvastatin Calcium346$5,027
AlogliptinAlogliptin Benzoate17$4,639
Gabapentin339$4,508
Levothyroxine Sodium329$4,466
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$4,282
Lisinopril240$3,463
Losartan Potassium232$3,417
Albuterol Sulfate HfaAlbuterol Sulfate86$3,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$246$18,46313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 635 physician assistant providers in New Mexico.

Other physician assistant in Rio Rancho

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →